# Johnson & Johnson Stock Hits 52-Week High After Strong Q2 Results: Is There More Upside?
Explore Johnson & Johnson's impressive Q2 2024 performance as shares trade near $169.56, approaching the top of their 52-week range. This episode analyzes how J&J beat analyst expectations and raised full-year guidance despite Stelara facing biosimilar competition. Learn why the Innovative Medicine business delivered nearly 5% year-over-year growth, with standout performances from key drugs like Darzalex, Tremfya, and Erleada.
We dive into analyst sentiment, revealing why major banks including Bank of America and RBC have raised their price targets to $173-175, suggesting modest upside potential. With a healthy 3% dividend yield and low beta, J&J maintains its status as a defensive healthcare blue chip. Discover what management's confident outlook for accelerating pharmaceutical sales means for investors and whether this healthcare giant remains a steady long-term investment as it navigates both challenges and opportunities in the second half of 2024.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
